A Digital Publication for the Practicing Medical Specialist, Industry Executive & Investor

No Carolina / New York

UroViu Corporation Receives FDA Clearance to Market Uro-G

UroViu Corporation, the developer of a suite of portable, self-contained and versatile single-use cystoscopy solutions, has received clearance from the U.S. Food and Drug Administration to market its third device: Uro-G, a flexible single-use cystoscope with a fully deflectable tip that enables physicians to perform interventional and diagnostic urologic procedures in their clinics conveniently in any room, anytime, without reprocessing.

This allows for practices to expand their cystoscopic capabilities and throughput without capital investments or service contracts. Typically, the per-procedure cost of owning and using a UroViu device is lower than for traditional reusable platforms.

“Early adopters of UroViu’s pioneering technology will value the practicality of this safe, user-friendly and effective option, both for practice and patients,” said Jed Kaminetsky M.D., clinical assistant professor of urology at the NYU Grossman School of Medicine and a medical director of Manhattan Medical Research. “In particular, we find the off-the-shelf availability of Uro-G to be extremely efficient and convenient in performing outpatient diagnostic procedures and stent  removals.”

Roger R. Dmochowski, M.D., professor of urologic surgery at Vanderbilt University Medical Center stated that “We are encouraged at the prospect of employing single-use devices that provide the same or better results for our patients without the heavy investment of time and capital in reprocessing”. He also appreciates the opportunity to avoid the risk of cross-contamination associated with reusable cannulas — which, in rare cases, have been linked with drug-resistant infections and even death. He added that the nimbleness, cost savings, and excellent safety profile of the Uro-G Cystoscope can result in fewer delays in the scheduling of diagnostic procedures, a crucial step in caring for patients.

UroViu will be introducing its full product range at this year’s American Urological Association (AUA) annual meeting on Sep 9-13th in Las Vegas, NV. Contact us for further information.


References:

  1. FDA is Investigating Reports of Infections Associated with Reprocessed Urological Endoscopes. FDA website. https://www.fda.gov/news-events/press-announcements/fda-investigating-reports-infections-associated-reprocessed-urological-endoscopes.Updated April 1, 2021. Accessed May 18, 2021.
Medical Device News Magazinehttps://infomeddnews.com
Medical Device News Magazine provides breaking medical device / biotechnology news. Our subscribers include medical specialists, device industry executives, investors, and other allied health professionals, as well as patients who are interested in researching various medical devices. We hope you find value in our easy-to-read publication and its overall objectives! Medical Device News Magazine is a division of PTM Healthcare Marketing, Inc. Pauline T. Mayer is the managing editor.

More News!

Dr. Sachita Shah, Sr. Director, Global Health, Butterfly Network, "Butterfly is proud to continue improving maternal health equity through Phase Two of the largest-scale handheld ultrasound distribution and training ever conducted in Sub-Saharan Africa. South Africa is an emerging market that continues to have disproportionately high rates of maternal mortality and stillbirth. Patients need easier access to antenatal imaging, and clinicians need better capabilities for screening high-risk conditions that lead to disproportionately worse pregnancy outcomes in rural areas in the public sector. Together with CHAI and GUSI, we can tackle this by making ultrasound much more accessible, so high-risk conditions can be identified earlier in care, which is known to improve outcomes.”
The clinical Study will enroll up to 97 patients at up to 12 European investigational sites. Completion of the study is expected this year, and results will support CE mark and pre-market approval submissions reports Vivasure Medical.
Dr. Michael Newman, Indaptus’ Founder, Chief Scientific Officer, and lead author, commented, “The new data are consistent with our preclinical animal tumor model studies and provide evidence for our hypothesis that patented Decoy bacteria can activate a wide range of innate and adaptive human immune cells involved in fighting tumors.  This aligns with what we’ve observed in our ongoing Phase 1 clinical trial of Decoy20 – broad immune activation, as evidenced by transiently increased levels of many key cytokines and chemokines following single dose administration. These findings bolster our confidence in Decoy20's potential as a multifaceted immunotherapy.”
To further understand the impact of platforms like TikTok on nutrition trends, MyFitnessPal partnered with Dublin City University on a research and experimental study that examined diet and nutrition content on TikTok. The study analyzed over 67,000 videos using Artificial Intelligence to compare them against public health and nutrition guidelines
Leveraging the power of Apple Vision Pro to seamlessly blend digital content with the physical world Osso Health brings the operating experience to life via detailed, clinically accurate workflows of common procedures.

By using this website you agree to accept Medical Device News Magazine Privacy Policy